

**ABUNDANCE INTERNATIONAL LIMITED**  
(Company Registration No.: 197501572K)  
(Incorporated in Singapore)

---

**RESPONSES TO SUBSTANTIAL AND RELEVANT QUESTIONS RECEIVED FROM  
SHAREHOLDER FOR THE ANNUAL GENERAL MEETING TO BE HELD ON 21 APRIL 2026**

---

The Board of Directors (the “**Board**” or “**Directors**”) of Abundance International Limited (the “**Company**”) and together with its subsidiaries, the “**Group**”) would like to thank shareholders for submitting questions ahead of the Company’s Annual General Meeting (“**AGM**”) to be held on Tuesday, 21 April 2026, at 10.00 a.m. at The JTC Summit, 8 Jurong Town Hall Road, Level 31, Singapore 609434.

Please refer to the Appendix setting out the Company’s response to substantial and relevant questions relating to the AGM resolutions received from shareholders. The Appendix also sets out the Company’s response to questions relating to our business outlook.

**By Order of the Board**

Sam Kok Yin  
Managing Director  
16 April 2026

*This announcement has been reviewed by the Company’s sponsor, PrimePartners Corporate Finance Pte. Ltd. (the “**Sponsor**”). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “**Exchange**”) and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Ms Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.*

## RESPONSES TO SHAREHOLDERS' QUESTIONS

### Question 1:

The Shareholder cited the following figures for the Company's performance in the previous financial years:

	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
<b>Net Income USD\$ '000</b>	-532	-536	-743	-2480	-2620	4830	1420	-300	276	-9160

In view of the Company's performance in the financial year ended 31 December 2025 ("FY2025") compared to the previous years, what are the causes for the relatively poorer performance, and in particular, why were the results as such despite the Company's active control measures.

Additionally, what would have been the projected loss if the Company had not disposed its current inventory to preserve cash flow last year.

#### Company's response:

The Company notes that the accurate correct figures for the Company's performance in the previous financial years are as follows: -

	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
<b>Net Income USD\$ '000</b>	-532	-536	-743	-2484	-2625	4827	1425	-300	276	-9157

The comparatively weaker performance in FY2025 was primarily attributable to the significant and sustained downturn in chemical market prices, particularly in the second half of the financial year. This was driven by softer global demand and increased pricing pressure across our key markets. Management had implemented measures such as tighter cost management, controlled procurement, and close monitoring of working capital; however, these were not sufficient to fully offset the external market conditions.

In light of the deteriorating market environment, the Company made a strategic decision to reduce its inventory levels. This was not only to manage storage costs, but more importantly to preserve cash flow, reduce exposure to further price declines, and avoid additional inventory write-down risks.

Looking ahead, market conditions remain uncertain and the Company is unable to provide guidance on the timing of a recovery. We will continue to focus on prudent cost management and disciplined inventory control while remaining responsive to market developments.

### Question 2:

Is the Company's chemical business expected to recover to a profit under the current prevailing market condition (taking into account the ongoing conflict driving chemical prices higher).

Company's response:

The outlook for the Company's chemical business remains uncertain under the current market conditions. While recent geopolitical developments have contributed to some upward pressure on chemical prices, demand recovery across key end-markets remains uneven and visibility is still limited.

As such, it is premature to conclude that the business will return to profitability in the near term solely based on current price movements. Any sustained recovery will depend not only on pricing, but also on the stability of demand, inventory levels across the supply chain, and broader economic conditions.

The Company will continue to monitor developments closely, but at this stage, we remain cautious and are unable to provide definitive guidance on the timing of a return to profitability.

**Question 3:**

Does the Company intend to expand outside of China given that revenue from China had slowed considerably?

Company's response:

While China remains a core market given the Company's established infrastructure and strong industry relationships, the Company also serves overseas markets including Taiwan, Japan, and Southeast Asia.

Considering current supply and demand conditions, the Company has stepped up its efforts to expand sales into these overseas markets in the upcoming financial year to diversify its revenue base and mitigate concentration risks.

**Question 4:**

The Shareholder noted the gearing ratio below:

	FY2025	FY 2024	FY 2023	FY 2022	FY 2021
Gearing Ratio	1.38	0.95	0.85	0.84	1.05
Liability (US\$'000)	40,590	35,224	30,639	32,123	38,868
Equity (US\$'000)	29,457	37,108	36,136	38,195	36,974

Is the Company taking steps to pare down the liability of the business in view of the growing gearing ratio despite the gain on disposal of shares in Shanghai Sunrise Polymer Material Co., Ltd.

Is the Company intending to raise more funds in the equity markets bring down the gearing ratio?

Company's response:

The increase in the Group's gearing ratio in FY2025 was primarily due to the losses recorded during the year, which reduced the Group's equity base, notwithstanding the gain from the disposal of shares in Shanghai Sunrise Polymer Material Co., Ltd.

As at the end of FY2025, the Group's financial position remains stable, with total assets of USD71.2 million against total liabilities of USD41.8 million, and current assets of USD53.5 million exceeding current liabilities of USD38.4 million. This reflects that the Group continues to maintain a sound liquidity position.

The Company will continue to monitor its gearing levels closely and exercise prudence in managing its balance sheet.

At this juncture, the Group does not have a need, nor any intention, to raise additional capital through the equity markets.

**Question 5:**

Referring to the Company's announcement dated 13 March 2026, regarding the entry into a licensing agreement, does the Company have the capability to commercialise and develop CypH-11, the agent capable of detecting viable tumour cells ("**CypH-11**") in the event of approval, or if the Company has to source for another business partner to utilise the exclusive license?

Company's response:

The licensor, Molecular Targeting Technologies, Inc. ("**MTTI**"), currently outsources the production of CypH-11 to a Good Manufacturing Practice ("**GMP**")-compliant facility in the United States. Under the licensing arrangement, MTTI will supply the required quantities of CypH-11 for the Company's testing and clinical trial activities within the target territories.

In the event that regulatory approval is obtained, the Company's strategy is to collaborate with an established pharmaceutical partner for the production and commercialisation of the product, or alternatively, to outsource manufacturing to a GMP-compliant facility. This approach allows the Company to leverage established expertise and infrastructure, while focusing on regulatory, market development, and commercial execution within its licensed territories.

**Question 6:**

Will the Company take any steps towards addressing its stagnating share prices? Will the Company consider share buybacks? Does the Company intend commission a report from trading houses in the near future, focusing what on the Company's future plans such as the commercialisation and production of CypH-11.

Company's response:

The Board remains mindful of the Company's share price performance and the importance of delivering sustainable shareholder returns. Notwithstanding the losses in FY2025, the Group continued to return value to shareholders by proposing dividends for shareholders' approval at the upcoming AGM, supported by gains from the disposal of shares in Shanghai Sunrise Polymer Material Co., Ltd.

With respect to share buybacks, the Board will consider seeking a mandate from shareholders in due course, if deemed appropriate, taking into account market conditions, the Company's financial position, and capital allocation priorities.

The Company recognises the importance of market visibility and will continue to provide updates on the development of the Company's wholly-owned subsidiary, Abundance Specialty Chemicals Pte. Ltd. and the progress of the commercialization and production of CypH-11.

**Question 7:**

In relation to the Company announcement on 30 June 2025, did the Company provide any funding for the joint venture and whether there have been any further investment discussions.

Company's response:

As of the date of the announcement, the Company did not provide any funding in relation to the joint venture. Following the termination of the joint venture, there have also been no further investment discussions with the former joint venture parties.